A Practical Approach to Myositis-Specific Antibodies https://t.co/14qow6zhsD

True or False: In a Japanese study of refractory neuropsychiatric SLE, rituximab led to significant improvement in the majority of patients treated. See if you got it right at https://t.co/3F1h89Qrtw https://t.co/vx0ILsZ3WF

NLRP3 inflammasome activation triggers PAD (2, 4) release from human neutrophils, increasing citrullination of intracellular proteins (CCPs) and driving the pathogenesis of #RA. Further proof: , PAD concentrations and PAD activity correlate with IL-1β.https://t.co/pRQy0ECG5d https://t.co/HExIhebJ4u

ABA versus HCQ in Palindromic Rheumatism Palindromic rheumatism may develop rheumatoid arthritis (RA) and could be an at-risk population. A pilot trial compared abatacept (ABA) versus hydroxychloroquine and demonstrated ABA reduces RA development in a 2 year study. https://t.co/XPP7CSxGad

Study of 305 newly Dx axSpA pts (age 38 yrs; 55% male, Dx delay 6yrs, 75% B27+). Clinical Dx, without Xray/imaging in 12%, 5% developed sacroiliitis during 8 yr F/U. r-axSpA mostly male w/ ^CRP https://t.co/zWJDRdBSWC https://t.co/nWFnEgp5Zf

Update on Multicentric Reticulohistiocytosis Have you ever seen multicentric reticulohistiocytosis (MRH)? Don't worry, it's a rare non-Langerhans cell histiocytosis condition characterized by papulonodular skin lesions and symmetric erosive polyarthritis, and it has only been https://t.co/1VrT8HFmva

FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/7se6qLsQoP https://t.co/64wC94hTTq

Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs

Fatigue in SLE An NIH lupus cohort study looked at fatigue in SLE and found associations with organ damage, obesity, but does not correlate with disease activity in systemic lupus erythematosus (SLE) patients. https://t.co/63JVDUwu88 https://t.co/3dPOThMbMD

Can’t attend #EULAR2026? You won’t miss a thing. RheumNow delivers: 📬 Daily summaries 🎥 Interviews 📊 Key data highlights Follow https://t.co/V10S4oVFsv June 3–6. https://t.co/7Xdj94eFu4